Literature DB >> 17478427

Transglutaminase 2 kinase activity facilitates protein kinase A-induced phosphorylation of retinoblastoma protein.

Suresh Mishra1, Gerry Melino2, Liam J Murphy3.   

Abstract

Transglutaminase 2 (TG2, tissue transglutaminase) is a multifunctional protein involved in cross-linking a variety of proteins, including retinoblastoma protein (Rb). Here we show that Rb is also a substrate for the recently identified serine/threonine kinase activity of TG2 and that TG2 phosphorylates Rb at the critically important Ser780 residue. Furthermore, phosphorylation of Rb by TG2 destabilizes the Rb.E2F1 complex. TG2 phosphorylation of Rb was abrogated by high Ca2+ concentrations, whereas TG2 transamidating activity was inhibited by ATP. TG2 was itself phosphorylated by protein kinase A (PKA). Phosphorylation of TG2 by PKA attenuated its transamidating activity and enhanced its kinase activity. Activation of PKA in mouse embryonic fibroblasts (MEF) with dibutyryl-cAMP enhanced phosphorylation of both TG2 and Rb by a process that was inhibited by the PKA inhibitor H89. Treatment with dibutyryl-cAMP enhanced Rb phosphorylation in MEFtg2+/+ cells but not in MEFtg2-/- cells. These data indicate that Rb is a substrate for TG2 kinase activity and suggest that phosphorylation of Rb, which results from activation of PKA in fibroblasts, is indirect and requires TG2 kinase activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17478427     DOI: 10.1074/jbc.M607413200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

Review 1.  Transglutaminase 2: a molecular Swiss army knife.

Authors:  Soner Gundemir; Gozde Colak; Janusz Tucholski; Gail V W Johnson
Journal:  Biochim Biophys Acta       Date:  2011-10-10

Review 2.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

Review 3.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

4.  Transglutaminase 2 facilitates or ameliorates HIF signaling and ischemic cell death depending on its conformation and localization.

Authors:  Soner Gundemir; Gozde Colak; Julianne Feola; Richard Blouin; Gail V W Johnson
Journal:  Biochim Biophys Acta       Date:  2012-10-17

Review 5.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

6.  Extracellular transglutaminase 2 has a role in cell adhesion, whereas intracellular transglutaminase 2 is involved in regulation of endothelial cell proliferation and apoptosis.

Authors:  C Nadalutti; K M Viiri; K Kaukinen; M Mäki; K Lindfors
Journal:  Cell Prolif       Date:  2011-02       Impact factor: 6.831

7.  Transglutaminase in Receptor and Neurotransmitter-Regulated Functions.

Authors:  Nancy A Muma
Journal:  Med One       Date:  2018-12-05

8.  Transglutaminase-1 regulates renal epithelial cell proliferation through activation of Stat-3.

Authors:  Zhu Zhang; Jingping Xing; Li Ma; Rujun Gong; Y Eugene Chin; Shougang Zhuang
Journal:  J Biol Chem       Date:  2008-12-02       Impact factor: 5.157

9.  Transglutaminase-1 protects renal epithelial cells from hydrogen peroxide-induced apoptosis through activation of STAT3 and AKT signaling pathways.

Authors:  Murugavel Ponnusamy; Maoyin Pang; Pavan Kumar Annamaraju; Zhu Zhang; Rujun Gong; Y Eugene Chin; Shougang Zhuang
Journal:  Am J Physiol Renal Physiol       Date:  2009-08-26

10.  Modulation of transglutaminase 2 activity in H9c2 cells by PKC and PKA signalling: a role for transglutaminase 2 in cytoprotection.

Authors:  Ibtesam Almami; John M Dickenson; Alan J Hargreaves; Philip L R Bonner
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.